Table 1 Summary of complete response cases with nivolumab treatment for Stage IV gastric cancer
References | Year | Age | Sex | Initial treatment | Metastasis (recurrence) | Number of chemotherapy regimens prior to nivolumab | Course of nivolumab | Post-nivolumab surgery | Post nivolumab chemotherapy | Adverse events | Prognosis |
|---|---|---|---|---|---|---|---|---|---|---|---|
Dai et al. [13] | 2022 | 66 | M | Palliative surgery | Liver | 1 | 8 | Hepatectomy | None | Immune pneumonia | 32 months |
Toyota et al. [14] | 2022 | 73 | M | Chemotherapy | Liver (invasion) | None | 5 | Distal gastrectomy and hepatectomy | S-1 | None | N/A |
Pan et al. [15] | 2022 | 45 | M | Chemotherapy | Liver, lung, lymph nodes | 3 | 5 | Total gastrectomy | Nivolumab | Exfoliative dermatitis eruption | 4 years |
Takami et al. [16] | 2021 | 70 | F | Total gastrectomy | Peritoneal dissemination, lymph nodes | 2 | 54 | None | Nivolumab | None | 7 years |
Watanabe et al. [17] | 2021 | 73 | M | Chemotherapy | Liver | 2 | 31 | Total gastrectomy | None | None | 43 months |
Kumamoto et al. [18] | 2021 | 69 | M | Chemotherapy | Lymph nodes | 2 | 8 | Esophagectomy | None | None | Over 12 months |
Komo et al. [19] | 2021 | 69 | F | Chemotherapy | Peritoneal dissemination | 2 | 9 | None | None | Immune pneumonia | Over 20 months |
Matsumoto et al. [9] | 2020 | 63 | F | Chemotherapy | Liver, lung | 2 | 26 | Distal gastrectomy | Nivolumab | None | 41 months |
Kuhara et al. [20] | 2020 | 60 | F | Chemotherapy | Lymph nodes | 2 | 39 | None | Nivolumab | Rash | Over 48 months |
Toyota et al. [21] | 2020 | 75 | M | Chemotherapy | Peritoneal dissemination | 2 | 23 | Distal gastrectomy | None | None | Over 20 months |
Toyota et al. [22] | 2020 | 70 | M | Chemotherapy | Pancreas and spleen (invasion), lymph nodes | 2 | 24 | Total gastrectomy with distal pancreatosplenectomy | None | Rash, gland hypofunction | Over 20 months |
Kashima et al. [23] | 2019 | 25 | M | Chemotherapy | Lymph nodes | 1 | 48 | Total gastrectomy | Nivolumab | None | Over 60 months |
Namikawa et al. [24] | 2018 | 77 | M | Total gastrectomy | Spleen, liver | 2 | 16 | None | Nivolumab | None | 28 months |